Stimulation of the ACE2/Ang-(1-7)/Mas axis in hypertensive pregnant rats attenuates cardiovascular dysfunction in adult male offspring

Hypertens Res. 2019 Dec;42(12):1883-1893. doi: 10.1038/s41440-019-0321-8. Epub 2019 Sep 10.

Abstract

The aim of this study was to investigate whether treatment with diminazene aceturate (DIZE), a putative ACE2 activator, or with angiotensin-(1-7) during pregnancy could attenuate the development of cardiovascular dysfunction in the adult offspring of spontaneously hypertensive rats (SHRs). For this, pregnant SHRs received DIZE or Ang-(1-7) throughout gestation. The systolic blood pressure (SBP) was measured in the male offspring from the 6th to16th weeks of age by tail-cuff plethysmography. Thereafter, the left ventricular contractile function and coronary reactivity were evaluated by the Langendorff technique. Samples of the left ventricles (LVs) and kidneys were collected for histology and western blot assay in another batch of adult rat offspring. Maternal treatment with DIZE or Ang-(1-7) during pregnancy attenuated the increase in SBP in adult offspring. In addition, both DIZE and Ang-(1-7) treatments reduced the cardiomyocyte diameter and fibrosis deposition in the LV, and treatment with Ang-(1-7) also reduced the fibrosis deposition in the kidneys. Maternal treatment with DIZE, as well as Ang-(1-7), improved the coronary vasodilation induced by bradykinin in isolated hearts from adult offspring. However, no difference was observed in the contractile function of the LVs of these animals. The expression levels of AT1 and Mas receptors, ACE, ACE2, SOD, and catalase in the LV were not modified by maternal treatment with Ang-(1-7), but this treatment elicited a reduction in AT2 expression. These data show that treatment with DIZE or Ang-(1-7) during gestation promoted beneficial effects of attenuating hypertension and cardiac remodeling in adult offspring.

Keywords: ACE2; Angiotensin-(1–7); Cardiac fibrosis; Cardiac hypertrophy; Diminazene aceturate; Hypertension.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin I / pharmacology*
  • Angiotensin-Converting Enzyme 2
  • Animals
  • Blood Pressure / drug effects
  • Cardiovascular Diseases / prevention & control*
  • Diminazene / analogs & derivatives*
  • Diminazene / pharmacology
  • Enzyme Activators / pharmacology*
  • Female
  • Heart / drug effects
  • Hypertension, Pregnancy-Induced / drug therapy*
  • Kidney / drug effects
  • Male
  • Myocardial Contraction
  • Peptide Fragments / pharmacology*
  • Peptidyl-Dipeptidase A / drug effects*
  • Pregnancy
  • Prenatal Exposure Delayed Effects
  • Rats
  • Ventricular Function, Left

Substances

  • Enzyme Activators
  • Peptide Fragments
  • Angiotensin I
  • Peptidyl-Dipeptidase A
  • Ace2 protein, rat
  • Angiotensin-Converting Enzyme 2
  • angiotensin I (1-7)
  • diminazene aceturate
  • Diminazene